Likewise, we identified CCL22 as the highest validated prognostic signature in 12 TCGA cancers (Fig. 6b, the highest bar); Moreover, we know it acts as a chemokine contributing to the modification of tumor microenvironment and resistance to the immune system [32]. This evidence concerns the gene CCL22 and neoplasm.